Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats

International Journal of Molecular Sciences

Volumn 13, Issue 2, 2012, Pages 2276-2289

  Alisi, Anna ^a   Pastore, Anna ^a   Ceccarelli, Sara ^a   Panera, Nadia ^a   Gnani, Daniela ^a   Bruscalupi, Giovannella ^b   Massimi, Mara ^c   Tozzi, Giulia ^a   Piemonte, Fiorella ^a   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Emodin; Hepatosteatosis; High fat diet; High fructose diet; Redox status

Indexed keywords

EMODIN; GLUTATHIONE; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR NECROSIS FACTOR ALPHA; REACTIVE OXYGEN SPECIES;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFECT; DRUG MECHANISM; GLUTATHIONE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOPRECIPITATION; INTERMETHOD COMPARISON; LIPID STORAGE; LIVER CELL; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION REDUCTION STATE; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMALS; CELL SURVIVAL; DIET, HIGH-FAT; DRUG EFFECTS; FATTY LIVER; INFLAMMATION; LIPID METABOLISM; LIVER; METABOLISM; OXIDATION-REDUCTION; OXIDATIVE STRESS; PATHOLOGY; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

ANIMALS; CELL SURVIVAL; DIET, HIGH-FAT; EMODIN; FATTY LIVER; INFLAMMATION; LIPID METABOLISM; LIVER; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

EID: 84857667774     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13022276     Document Type: Article

References (54)

1. Mantena, S.K.; King, A.L.; Andringa, K.K., Eccleston, H.B.; Bailey, S.M. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radical Biol. Med. 2008, 44, 1259-1272.
2. Clément, S.; Negro, F. Hepatitis C Virus: The viral way to fatty liver. J. Hepatol. 2007, 46, 985-987.
3. Wree, A.; Kahraman, A.; Gerken, G.; Canbay, A. Obesity affects the liver-the link between adipocytes and hepatocytes. Digestion 2011, 83, 124-133.
4. Khashab, M.A.; Liangpunsakul, S.; Chalasani, N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr. Gastroenterol. Rep. 2008, 10, 73-80.
5. Alisi, A.; Feldstein, A.E.; Villani, A.; Raponi, M.; Nobili, V. Nonalcoholic fatty liver disease: A multidisciplinary approach. Nat. Rev. Gastroenterol. Hepatol. 2012, in press.
6. Brunt, E.M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 195-203.
7. Feldstein, A.E. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin. Liver Dis. 2010, 30, 391-401.
8. Moore, J.B. Non-alcoholic fatty liver disease: The hepatic consequence of obesity and the metabolic syndrome. Proc. Nutr. Soc. 2010, 69, 211-220.
9. Day, C.P.; James, O.F. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998, 114, 842-845.
10. Bugianesi, E.; Moscatiello, S.; Ciaravella, M.F.; Marchesini, G. Insulin resistance in nonalcoholic fatty liver disease. Curr. Pharm. Des. 2010, 16, 1941-1951.
11. Feldstein, A.E.; Charatcharoenwitthaya, P.; Treeprasertsuk, S.; Benson, J.T.; Enders, F.B.; Angulo, P. The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. Gut 2009, 58, 1538-1544.
12. Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Human fatty liver disease: Old questions and new insights. Science 2011, 332, 1519-1523.
13. Albano, E.; Mottaran, E.; Occhino, G.; Reale, E.; Vidali, M. Review article: Role of oxidative stress in the progression of non-alcoholic steatosis. Aliment. Pharmacol. Ther. 2005, 22, 71-73.
14. Tarantino, G.; Savastano, S.; Colao, A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J. Gastroenterol. 2010, 16, 4773-4783.
15. Alisi, A.; Carsetti, R.; Nobili, V. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology 2011, 54, 1500-1502.
16. Alisi, A.; Nobili, V. Nonalcoholic fatty liver disease: Targeted therapy in children-what is the right way? Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 425-426.
17. Lavine, J.E.; Schwimmer, J.B.; Van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N. et al. Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305, 1659-1668.
18. Pradeep, K.; Mohan, C.V.; Gobianand, K.; Karthikeyan, S. Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. Eur. J. Pharmacol. 2007, 560, 110-116.
19. Comar, K.M.; Kirby, D.F. Herbal remedies in gastroenterology. J. Clin. Gastroenterol. 2005, 39, 457-468.
20. Di Sario, A.; Bendia, E.; Taffetani, S.; Omenetti, A.; Candelaresi, C.; Marzioni, M.; De Minicis, S.; Benedetti, A. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Dig. Liver Dis. 2005, 37, 869-876.
21. Loguercio, C.; Federico, A.; Trappoliere, M.; Tuccillo, C.; de Sio, I.; Di Leva, A.; Niosi, M.; D'Auria, M.V.; Papasso, R.; Del Vecchio Blanco, C. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig. Dis. Sci. 2007, 52, 2387-2395.
22. Shapiro, H.; Bruck, R. Therapeutic potential of curcumin in non-alcoholic steatohepatitis. Nutr. Res. Rev. 2005, 18, 212-221.
23. Jang, E.M.; Choi, M.S.; Jung, U.J.; Kim, M.J.; Kim, H.J.; Jeon, S.M.; Shin, S.K.; Seong, C.N.; Lee, M.K. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 2008, 57, 1576-1583.
24. Tang, Y.; Zheng, S.; Chen, A. Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 2009, 150, 3011-3020.
25. Dong, H.; Lu, F.E.; Gao, Z.Q.; Xu, L.J.; Wang, K.F.; Zou, X. Effetcs of emodin on treating murine nonalcohlic fatty liver induced by high caloric laboratory chaw. World J. Gastroenterol. 2005, 11, 1339-1344.
26. Samuel, V.T. Fructose induced lipogenesis: From sugar to fat to insulin resistance. Trends Endocrinol. Metab. 2011, 22, 60-65.
27. Lim, J.S.; Mietus-Snyder, M.; Valente, A.; Schwarz, J.M.; Lustig, R.H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 251-264.
28. Spruss, A.; Bergheim, I. Dietary fructose and intestinal barrier: Potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2009, 20, 657-662.
29. Alisi, A.; Manco, M.; Pezzullo, M.; Nobili, V. Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis. Hepatology 2011, 53, 372-373.
30. Kohli, R.; Kirby, M.; Xanthakos, S.A.; Softic, S.; Feldstein, A.E.; Saxena, V.; Tang, P.H.; Miles, L.; Miles, M.V.; Balistreri, W.F. et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010, 52, 934-944.
31. Alisi, A.; Da Sacco, L.; Bruscalupi, G.; Piemonte, F.; Panera, N.; De Vito, R.; Leoni, S.; Bottazzo, G.F.; Masotti, A.; Nobili, V. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab. Invest. 2011, 91, 283-293.
32. Tiniakos, D.G. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Histological diagnostic criteria and scoring systems. Eur. J. Gastroenterol. Hepatol. 2010, 22, 643-650.
33. Hebbard, L.; George, J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 35-44.
34. Lin, C.C.; Chang, C.H.; Yang, J.J.; Namba, T.; Hattori, M. Hepatoprotective effects of emodin from Ventilago leiocarpa. J. Ethnopharmacol. 1996, 52, 107-111.
35. Dong, M.X.; Jia, Y.; Zhang, Y.B.; Li, C.C.; Geng, Y.T.; Zhou, L.; Li, X.Y.; Liu, J.C.; Niu, Y.C. Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation. World J. Gastroenterol. 2009, 15, 4753-4762.
36. Zhao, Y.L.; Wang, J.B.; Zhou, G.D.; Shan, L.M.; Xiao, X.H. Investigations of free anthraquinones from rhubarb against α-naphthylisothiocyanate-induced cholestatic liver injury in rats. Basic Clin. Pharmacol. Toxicol. 2009, 104, 463-469.
37. Srinivas, G.; Anto, R.J.; Srinivas, P.; Vidhyalakshmi, S.; Senan, V.P.; Karunagaran, D. Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9. Eur. J. Pharmacol. 2003, 473, 117-125.
38. Ding, Y.; Zhao, L.; Mei, H.; Zhang, S.L.; Huang, Z.H.; Duan, Y.Y.; Ye, P. Exploration of Emodin to treat α-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway. Eur. J. Pharmacol. 2008, 590, 377-386.
39. Hsu, C.M.; Hsu, Y.A.; Tsai, Y.; Shieh, F.K.; Huang, S.H.; Wan, L.; Tsai, F.J. Emodin inhibits the growth of hepatoma cells: finding the common anti-cancer pathway using Huh7, Hep3B, and HepG2 cells. Biochem. Biophys. Res. Commun. 2010, 392, 473-478.
40. Zhan, Y.; Li, D.; Wei, H.; Wang, Z.; Huang, X.; Xu, Q.; Lu, H. Emodin on hepatic fibrosis in rats. Chin. Med. J. 2000, 113, 599-601.
41. Tilg, H. The role of cytokines in non-alcoholic fatty liver disease. Dig. Dis. 2010, 28, 179-185.
42. Tetri, L.H.; Basaranoglu, M.; Brunt, E.M.; Yerian, L.M.; Neuschwander-Tetri, B.A. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G987-G995.
43. Bertola, A.; Bonnafous, S.; Anty, R.; Patouraux, S.; Saint-Paul, M.C.; Iannelli, A.; Gugenheim, J.; Barr, J.; Mato, J.M.; Le Marchand-Brustel, Y. et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 2010, 5, e13577.
44. Ferreira, A.V.; Mario, E.G.; Porto, L.C.; Andrade, S.P.; Botion, L.M. High-carbohydrate diet selectively induces tumor necrosis factor-α production in mice liver. Inflammation 2011, 34, 139-145.
45. Han, D.; Hanawa, N.; Saberi, B.; Kaplowitz, N. Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, G1-G7.
46. Alisi, A.; Piemonte, F.; Pastore, A.; Panera, N.; Passatelli, C.; Tozzi, G.; Petrini, S.; Pietrobattista, A.; Bottazzo, G.F.; Nobili, V. Glutathionylation of p65NF-kappaB correlates with proliferating/apoptotic hepatoma cells exposed to pro- and anti-oxidants. Int. J. Mol. Med. 2009, 24, 319-326.
47. Yu, C.X.; Li, S.; Whorton, A.R. Redox regulation of PTEN by S-nitrosothiols. Mol. Pharmacol. 2005, 68, 847-854.
48. Alisi, A.; Bruscalupi, G.; Pastore, A.; Petrini, S.; Panera, N.; Massimi, M.; Tozzi, G.; Leoni, S.; Piemonte, F.; Nobili, V. Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis. J. Nutr. Biochem. 2012, 23, 169-178.
49. Peyrou, M.; Bourgoin, L.; Foti, M. PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer. Dig. Dis. 2010, 1, 236-246.
50. Vinciguerra, M.; Foti, M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann. Hepatol. 2008, 7, 192-199.
51. Hay, N. Akt isoforms and glucose homeostasis - the leptin connection. Trends Endocrinol. Metab. 2011, 22, 66-73.
52. Leoni, S.; Spagnuolo, S.; Massimi, M.; Terenzi, F.; Conti Devirgiliis, L. Amino acid uptake regulation by cell growth in cultured hepatocytes isolated from fetal and adult rats. Biosci. Rep. 1992, 12, 135-141.
53. Pastore, A.; Federici, G.; Bertini, E.; Piemonte, F. Analysis of glutathione: implication in redox and detoxification. Clin. Chim. Acta 2003, 333, 19-39.
54. Babich, H.; Borenfreund, E. Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay. Appl. Environ. Microbiol. 1991, 57, 2101-2103.